Division of Critical Care Medicine and Trauma, National Hospital Organization Disaster Medical Center, 3256 Midori-cho, Tachikawa, Tokyo, 190-0014 Japan.
J Intensive Care. 2014 Feb 21;2(1):16. doi: 10.1186/2052-0492-2-16. eCollection 2014.
Supplemental landiolol administration (20 or 40 μg kg(-1) min(-1)) effectively diminished harmful hemodynamic changes during bronchoscopic endotracheal suctioning compared to normal saline. However, inappropriate use of landiolol (i.e., failure of evaluating factors that influence hemodynamic changes) may iatrogenically further complicate pathophysiology, and relatively higher doses of landiolol may be dangerous. We recommend that landiolol should not be routinely used to control cardiovascular responses during bronchoscopic endotracheal suctioning in the intensive care unit. Careful evaluation of factors influencing hemodynamic changes and close monitoring of the patient are mandatory following landiolol administration. Furthermore, a lower initiation dose is recommended.
补充性兰地洛尔给药（20 或 40μg/kg/min）与生理盐水相比，可有效减轻支气管镜经鼻气管内吸引过程中的有害血流动力学变化。然而，兰地洛尔的不恰当使用（即未能评估影响血流动力学变化的因素）可能会加重医源性病理生理学改变，且相对较高剂量的兰地洛尔可能存在危险。我们建议，兰地洛尔不应常规用于 ICU 中支气管镜经鼻气管内吸引过程中的心血管反应控制。兰地洛尔给药后，必须仔细评估影响血流动力学变化的因素并密切监测患者。此外，建议起始剂量更低。
